# CitroTech Inc.: overview CITR · NYSE · CIK 894556 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/citr.md) · [Financials](/companies/citr/financials.md) · [Filings](/companies/citr/filings.md) · [Insiders](/companies/citr/insiders.md) Latest reported revenue: [$280.7k](/filings/0001683168-26-006123.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q/A filed Aug 10, 2026 (XBRL us-gaap:Revenues, accession 0001683168-26-006123). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [107](/filings/0001640334-25-002055.md) | [69.6 d](/filings/0001683168-26-002356.md) | [969](/filings/0001683168-26-003943.md) | [688](/filings/0001683168-26-006123.md) | [288](/filings/0001640334-25-002055.md) | [436 d](/filings/0001683168-26-002356.md) | [345](/filings/0001683168-26-003943.md) | [281](/filings/0001683168-26-006123.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(524.4%)](/filings/0001640334-25-002055.md) | [(1722.2%) d](/filings/0001683168-26-002356.md) | [(356.8%)](/filings/0001683168-26-003943.md) | [(438.8%)](/filings/0001683168-26-006123.md) | [(1470.3%)](/filings/0001640334-25-002055.md) | [(1325.7%) d](/filings/0001683168-26-002356.md) | [(1289.3%)](/filings/0001683168-26-003943.md) | [(1244.9%)](/filings/0001683168-26-006123.md) | | Net margin | % | [(612.1%)](/filings/0001640334-25-002055.md) | [(2583.7%) d](/filings/0001683168-26-002356.md) | [(1124.8%)](/filings/0001683168-26-006123.md) | [(1731.1%)](/filings/0001683168-26-006123.md) | [(2751.2%)](/filings/0001640334-25-002055.md) | [(1398.8%) d](/filings/0001683168-26-002356.md) | [(1800.6%)](/filings/0001683168-26-006123.md) | [(1390.5%)](/filings/0001683168-26-006123.md) | | Diluted EPS | $ per share | [(0.11)](/filings/0001640334-25-002055.md) | not reported | [(1.37)](/filings/0001683168-26-003943.md) | [(1.14)](/filings/0001683168-26-006123.md) | [(0.59)](/filings/0001640334-25-002055.md) | not reported | [(0.33)](/filings/0001683168-26-003943.md) | [(0.18)](/filings/0001683168-26-006123.md) | | Free cash flow | $k | [(551) d](/filings/0001640334-25-002055.md) | [(618) d](/filings/0001683168-26-002356.md) | [(741)](/filings/0001683168-26-003943.md) | [(1,352) d](/filings/0001683168-26-006123.md) | [(1,515) d](/filings/0001640334-25-002055.md) | [(2,510) d](/filings/0001683168-26-002356.md) | [(2,070)](/filings/0001683168-26-003943.md) | [(1,783) d](/filings/0001683168-26-006123.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001640334-23-000526.md) | [62.7](/filings/0001640334-24-001174.md) | [521](/filings/0001640334-25-000558.md) | [808](/filings/0001683168-26-002356.md) | [2,381](/filings/0001683168-26-002356.md) | | Gross margin | % | not reported | [97.0%](/filings/0001640334-24-000667.md) | [74.4%](/filings/0001640334-24-000667.md) | not reported | not reported | | Operating margin | % | not reported | [(4652.4%)](/filings/0001640334-24-001174.md) | [(1939.5%)](/filings/0001640334-25-000558.md) | [(656.2%)](/filings/0001683168-26-002356.md) | [(692.7%)](/filings/0001683168-26-002356.md) | | Net margin | % | not reported | [(4635.3%)](/filings/0001640334-24-001174.md) | [(1940.3%)](/filings/0001640334-25-000558.md) | [(851.3%)](/filings/0001683168-26-002356.md) | [(1546.9%)](/filings/0001683168-26-002356.md) | | Diluted EPS | $ per share | [0.00](/filings/0001640334-23-000526.md) | [0.00](/filings/0001640334-24-001174.md) | [(0.10)](/filings/0001640334-25-000558.md) | [(0.82)](/filings/0001683168-26-002356.md) | [(2.96)](/filings/0001683168-26-002356.md) | | Free cash flow | $k | [(24.2)](/filings/0001640334-23-000526.md) | [(714)](/filings/0001640334-24-001174.md) | [(1,216)](/filings/0001640334-25-000558.md) | [(1,938)](/filings/0001683168-26-002356.md) | [(6,063)](/filings/0001683168-26-002356.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/citr/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-22 | [Huff Craig a](/insiders/1241947.md) | Director, 10% owner | Purchase (P) | 200,000 | $2.50 | $500.0k | [Form 4](/filings/0001193125-26-432001.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.7m | 486,620 | | Added +62,452 | | [FIFTH THIRD BANCORP](/funds/35527.md) | 2026-06-30 | $1.3m | 235,281 | | Added +114,111 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $973.3k | 176,239 | | Added +23,698 | | [Lotus Technology Management, LP](/funds/2095243.md) | 2026-06-30 | $750.0k | 750,000 | | Unchanged | | [Cerity Partners LLC](/funds/1566475.md) | 2026-06-30 | $559.0k | 101,275 | | New +101,275 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $522.3k | 94,625 | | Added +27,419 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $351.3k | 63,650 | | Added +52,000 | | [T3 Companies, LLC](/funds/2052441.md) | 2026-06-30 | $226.2k | 40,983 | | Added +15,983 | | [WEALTH ENHANCEMENT ADVISORY SERVICES, LLC](/funds/1632972.md) | 2026-06-30 | $211.1k | 40,825 | | New +40,825 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $209.6k | 37,969 | | Added +11,738 | ## Recent filings [All 266 filings](/companies/citr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 16:15 ET | [8-K](/filings/0001683168-26-008023.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-26-008023 | | 2026-10-01 | 19:05 ET | [S-1/A](/filings/0001683168-26-007510.md) | Registration statement, amended | 0001683168-26-007510 | | 2026-09-28 | 07:01 ET | [S-1](/filings/0001683168-26-007437.md) | Registration statement | 0001683168-26-007437 | | 2026-09-14 | 16:39 ET | [8-K](/filings/0001683168-26-007113.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-26-007113 | | 2026-08-10 | 06:04 ET | [10-Q/A](/filings/0001683168-26-006123.md) | Quarterly report, amended, period 2026-06-30 | 0001683168-26-006123 | | 2026-08-10 | 21:59 ET | [10-Q](/filings/0001683168-26-006119.md) | Quarterly report, period 2026-06-30 | 0001683168-26-006119 | | 2026-08-06 | 16:30 ET | [SCHEDULE 13D/A](/filings/0001640334-26-001288.md) | Ownership report, active investor, amended | 0001640334-26-001288 | | 2026-06-17 | 16:40 ET | [8-K](/filings/0001683168-26-004914.md) | 5.02 Departure or appointment of officers or directors | 0001683168-26-004914 | | 2026-06-03 | 17:14 ET | [SCHEDULE 13D/A](/filings/0001683168-26-004503.md) | Ownership report, active investor, amended | 0001683168-26-004503 | | 2026-06-01 | 18:06 ET | [SCHEDULE 13D/A](/filings/0001193125-26-251900.md) | Ownership report, active investor, amended | 0001193125-26-251900 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001683168-26-002356.md), filed Mar 30, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/33266e92-8939-46af-9f99-6bbb9200dfc9) ## About the filer - CIK: 894556 - Tickers: CITR - Exchange: NYSE - SIC code: 2800 Chemicals & Allied Products - State of incorporation: WY - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:31 ET. No prices; not investment advice.